While serum anti-MOG antibodies were positive, the clinical features, including progressive impairment of consciousness and hyponatremia, were atypical for MOGAD alone, leading to the identification of anti-GFAPα antibodies in the cerebrospinal fluid (CSF). The gene discussed is MOG; the disease is Hyponatremia.